Clinical issues and research in respiratory failure from severe acute respiratory syndrome.

The National Heart, Lung, and Blood Institute, along with the Centers for Disease Control and Prevention and the National Institute of Allergy and Infectious Diseases, convened a panel to develop recommendations for treatment, prevention, and research for respiratory failure from severe acute respiratory syndrome (SARS) and other newly emerging infections. The clinical and pathological features of acute lung injury (ALI) from SARS appear indistinguishable from ALI from other causes. The mainstay of treatments for ALI remains supportive. Patients with ALI from SARS who require mechanical ventilation should receive a lung protective, low tidal volume strategy. Adjuvant treatments recommended include prevention of venous thromboembolism, stress ulcer prophylaxis, and semirecumbent positioning during ventilation. Based on previous experience in Canada, infection control resources and protocols were recommended. Leadership structure, communication, training, and morale are an essential aspect of SARS management. A multicenter, placebo-controlled trial of corticosteroids for late SARS is justified because of widespread clinical use and uncertainties about relative risks and benefits. Studies of combined pathophysiologic endpoints were recommended, with mortality as a secondary endpoint. The group recommended preparation for studies, including protocols, ethical considerations, Web-based registries, and data entry systems.

[1]  B. Murphy,et al.  An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus , 2004, Nature Medicine.

[2]  H. Hsieh,et al.  Inhibition of Severe Acute Respiratory Syndrome Coronavirus Replication by Niclosamide , 2004, Antimicrobial Agents and Chemotherapy.

[3]  T. Kuiken,et al.  Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets , 2004, The Lancet.

[4]  W. Sibbald,et al.  Transmission of severe acute respiratory syndrome during intubation and mechanical ventilation. , 2004, American journal of respiratory and critical care medicine.

[5]  Christopher W. Wong,et al.  Laboratory-acquired severe acute respiratory syndrome. , 2004, The New England journal of medicine.

[6]  F. Aoki,et al.  Severe Acute Respiratory Syndrome-Related Coronavirus Is Inhibited by Interferon-α , 2004, The Journal of infectious diseases.

[7]  Michelle M. Packard,et al.  Prior Infection and Passive Transfer of Neutralizing Antibody Prevent Replication of Severe Acute Respiratory Syndrome Coronavirus in the Respiratory Tract of Mice , 2004, Journal of Virology.

[8]  A. Debnath,et al.  Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors , 2004, The Lancet.

[9]  Y. Guan,et al.  Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings , 2004, Thorax.

[10]  Wenhui Li,et al.  Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Ton de Jong,et al.  Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques , 2004, Nature Medicine.

[12]  Peter B. Jahrling,et al.  Interferon-β 1a and SARS Coronavirus Replication , 2004, Emerging infectious diseases.

[13]  J. Jernigan,et al.  Combining Clinical and Epidemiologic Features for Early Recognition of SARS , 2004, Emerging infectious diseases.

[14]  K. Kain,et al.  Severe Acute Respiratory Syndrome–associated Coronavirus in Lung Tissue , 2004, Emerging infectious diseases.

[15]  J. Dennis,et al.  Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. , 2003, JAMA.

[16]  G. Bernard.  Corticosteroids: the "terminator" of all untreatable serious pulmonary illness. , 2003, American Journal of Respiratory and Critical Care Medicine.

[17]  M. Chan-yeung,et al.  High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. , 2003, American journal of respiratory and critical care medicine.

[18]  O. Tsang,et al.  Coronavirus-positive Nasopharyngeal Aspirate as Predictor for Severe Acute Respiratory Syndrome Mortality , 2003, Emerging infectious diseases.

[19]  P. Khong,et al.  Severe acute respiratory syndrome: radiographic evaluation and clinical outcome measures. , 2003, Radiology.

[20]  Elizabeth J Phillips,et al.  Common Adverse Events Associated with the Use of Ribavirin for Severe Acute Respiratory Syndrome in Canada , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  N. Adhikari,et al.  A practical approach to airway management in patients with SARS. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[22]  T. Stewart,et al.  Communication in the Toronto critical care community: important lessons learned during SARS , 2003, Critical care.

[23]  M. Peiris,et al.  Infants born to mothers with severe acute respiratory syndrome. , 2003, Pediatrics.

[24]  G. Boivin,et al.  Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. , 2003, Antiviral research.

[25]  P. Hawkey,et al.  Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. , 2003, Journal of medical microbiology.

[26]  H. Doerr,et al.  Treatment of SARS with human interferons , 2003, The Lancet.

[27]  Arul Earnest,et al.  Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. , 2003, JAMA.

[28]  W. Travis,et al.  Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore , 2003, Human Pathology.

[29]  G. Zeng,et al.  Our strategies for fighting severe acute respiratory syndrome (SARS). , 2003, American journal of respiratory and critical care medicine.

[30]  H. Doerr,et al.  Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus , 2003, The Lancet.

[31]  Elizabeth Rea,et al.  Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. , 2003, JAMA.

[32]  J. Peiris,et al.  Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study , 2003, The Lancet.

[33]  Arthur S Slutsky,et al.  Identification of severe acute respiratory syndrome in Canada. , 2003, The New England journal of medicine.

[34]  Peter Cameron,et al.  A major outbreak of severe acute respiratory syndrome in Hong Kong. , 2003, The New England journal of medicine.

[35]  J. A. Comer,et al.  A novel coronavirus associated with severe acute respiratory syndrome. , 2003, The New England journal of medicine.

[36]  Michael B Edmond,et al.  Managing SARS amidst uncertainty. , 2003, The New England journal of medicine.

[37]  R. Maunder,et al.  The immediate psychological and occupational impact of the 2003 SARS outbreak in a teaching hospital. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[38]  S. Lapinsky,et al.  ICU management of severe acute respiratory syndrome , 2003, Intensive Care Medicine.

[39]  B. Thompson,et al.  Glucocorticoids and acute lung injury , 2003, Critical care medicine.

[40]  Arthur S Slutsky,et al.  One-year outcomes in survivors of the acute respiratory distress syndrome. , 2003, The New England journal of medicine.

[41]  S. Kaneko,et al.  Synergistic antiviral effect of a combination of mouse interferon‐α and interferon‐γ on mouse hepatitis virus , 2002, Journal of medical virology.

[42]  Isabelle Durand-Zaleski,et al.  Paresis acquired in the intensive care unit: a prospective multicenter study. , 2002, JAMA.

[43]  Darcy L Day,et al.  LUNG PROTECTIVE VENTILATION (LPV) FOR ACUTE LUNG INJURY (ALI) DOES NOT INCREASE SEDATION USE: Research Citation M , 2002 .

[44]  M. Niederman,et al.  Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. , 2002, Archives of internal medicine.

[45]  J. Kress,et al.  Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. , 2000, The New England journal of medicine.

[46]  D. Schoenfeld,et al.  Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. , 2000, The New England journal of medicine.

[47]  F. Mata,et al.  Incidence of gastroesophageal reflux and aspiration in mechanically ventilated patients using small-bore nasogastric tubes. , 2000, JPEN. Journal of parenteral and enteral nutrition.

[48]  G Sherman,et al.  Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. , 1999, Critical care medicine.

[49]  Y. Kupfer,et al.  Subcutaneous Heparin Prophylaxis Significantly Reduces The Incidence Of Venous Thromboembolic Events In The Critically Ill , 1999 .

[50]  Miquel Ferrer,et al.  Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomised trial , 1999, The Lancet.

[51]  A. Turpie,et al.  A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. , 1999, The New England journal of medicine.

[52]  G Sherman,et al.  The use of continuous i.v. sedation is associated with prolongation of mechanical ventilation. , 1998, Chest.

[53]  G. Meduri,et al.  Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. , 1998, JAMA.

[54]  G. Guyatt,et al.  A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. , 1998, The New England journal of medicine.

[55]  M. Fine,et al.  Quality of care, process, and outcomes in elderly patients with pneumonia. , 1997, JAMA.

[56]  E Angus,et al.  A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients. , 1997, Critical care medicine.

[57]  H. Champion,et al.  The impact of implementation of neuromuscular blockade monitoring standards in a surgical intensive care unit. , 1996, The American surgeon.

[58]  W S David,et al.  Muscle weakness in mechanically ventilated patients with severe asthma. , 1996, American journal of respiratory and critical care medicine.

[59]  R. Rodríguez-Roisín,et al.  Semirecumbent position protects from pulmonary aspiration but not completely from gastroesophageal reflux in mechanically ventilated patients. , 1995, American journal of respiratory and critical care medicine.

[60]  M. Magistris,et al.  Neuromuscular disorder in intensive care unit patients treated with pancuronium bromide. Occurrence in a cluster group of seven patients and two sporadic cases, with electrophysiologic and histologic examination. , 1994, Chest.

[61]  M. Lamy,et al.  The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. , 1994, American journal of respiratory and critical care medicine.

[62]  J. Ibáñez,et al.  Gastroesophageal reflux in intubated patients receiving enteral nutrition: effect of supine and semirecumbent positions. , 1992, JPEN. Journal of parenteral and enteral nutrition.

[63]  R. Rodríguez-Roisín,et al.  Pulmonary Aspiration of Gastric Contents in Patients Receiving Mechanical Ventilation: The Effect of Body Position , 1992, Annals of Internal Medicine.

[64]  J. Murray,et al.  Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. , 1988, The American review of respiratory disease.

[65]  C. Sprung,et al.  High-dose corticosteroids in patients with the adult respiratory distress syndrome. , 1987, The New England journal of medicine.

[66]  T. Clemmer,et al.  Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. , 1987, Chest.

[67]  A. Meyer,et al.  Sucralfate suspension versus titrated antacid for the prevention of acute stress-related gastrointestinal hemorrhage in critically ill patients , 1987 .

[68]  C. Meschievitz,et al.  Prevention of Experimental Coronavirus Colds with Intranasal α-2b Interferon , 1986, The Journal of infectious diseases.

[69]  J. Weigelt,et al.  Early steroid therapy for respiratory failure. , 1985, Archives of surgery.

[70]  D. Tyrrell,et al.  Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers , 1983, Antimicrobial Agents and Chemotherapy.

[71]  J. Cade.  High risk of the critically ill for venous thromboembolism , 1982, Critical care medicine.

[72]  C. Forbes,et al.  Prevention of Deep Vein Thrombosis in Medical Patients by Low-Dose Heparin , 1981, Scottish medical journal.

[73]  D. Matthews,et al.  IN VITRO ANTIVIRAL ACTIVITY OF HUMAN RHINOVIRUS 3C PROTEASE INHIBITORS AGAINST THE SARS CORONAVIRUS , 2004 .

[74]  Arthur S Slutsky,et al.  Critically ill patients with severe acute respiratory syndrome. , 2003, JAMA.

[75]  M. Fine,et al.  Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. , 2001, American journal of respiratory and critical care medicine.